SaraAHurvitzMD
Oncology • Santa Monica, CAProfessor of Medicine, University of California Los Angeles David Geffen SOM
Dr. Hurvitz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2336 Santa Monica Blvd., Suite 304
Santa Monica, CA 90404Phone+1 310-998-4747Fax+1 310-998-4747- Is this information wrong?
Summary
- Dr. Sara Hurvitz is an oncologist in Santa Monica, CA and is affiliated with UCLA Medical Center-Santa Monica. She received her medical degree from University of Southern California School of Medicine, did her residency training in internal medicine at UCLA, served as Chief Resident of Internal Medicine and then completed her hematology/oncology fellowship at UCLA. She has been in practice as a breast cancer medical oncologist since 2006. She has more than 100 publications and over 500 citings.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1999 - 2002
Keck School of Medicine of the University of Southern CaliforniaClass of 1999
Certifications & Licensure
WA State Medical License 2023 - 2026
CA State Medical License 2001 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Super Doctor SuperDoctors.com
Clinical Trials
- Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer Start of enrollment: 2005 May 01
- Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer Start of enrollment: 2008 Jul 01
- Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsGenomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study.Nicholas C Turner, A Douglas Laird, Melinda L Telli, Hope S Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A Mina, Judith Balmaña, Peter A Fasching, Sa...> ;NPJ Breast Cancer. 2023 Oct 6
- 3 citationsNeoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-lab...Sara A Hurvitz, Aditya Bardia, Vanesa Quiroga, Yeon Hee Park, Isabel Blancas, José Luis Alonso-Romero, Aleksandr Vasiliev, Hryhoriy Adamchuk, Marcelo Salgado, Denise A...> ;The Lancet. Oncology. 2023 Sep 1
- DESTINY-Breast03 trial: some questions remain - Authors' reply.Sara A Hurvitz, Giuseppe Curigliano, Anton Egorov, Shahid Ashfaque, Javier Cortés> ;Lancet. 2023 May 20
- Join now to see all
Journal Articles
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA MutationHope S Rugo, Sara A Hurvitz, Lida A Mina, The New England Journal of Medicine
- Quality of Life with Talazoparib Versus Physician’s Choice of Chemotherapy in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutation: Patient-Reported Outc...Sara Hurvitz, MD, Annals of Oncology
Lectures
- Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS)...2019 ASCO Annual Meeting - 6/1/2019
- Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive br...2019 ASCO Annual Meeting - 6/1/2019
- Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) adv...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Join now to see all
Authored Content
- Buparlisib plus Fulvestrant Versus Placebo plus Fulvestrant for Postmenopausal, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Advanced Breast Cancer: Overall Survival Results from BELLE-2October 2018
Press Mentions
1 NCCN Guidelines for Patients® Inflammatory Breast Cancer, 2023March 23rd, 2023- Advances in SERDs from the 2022 SABCSJanuary 12th, 2023
- Addressing Knowledge Gaps in Metastatic Triple-Negative Breast Cancer Treatment and CareJanuary 5th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
